Esperion Theraps Inc Company Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the competitive landscape for ESPERION THERAPS INC, and what generic alternatives to ESPERION THERAPS INC drugs are available?
ESPERION THERAPS INC has two approved drugs.
There are seven US patents protecting ESPERION THERAPS INC drugs.
There are forty-four patent family members on ESPERION THERAPS INC drugs in twenty-two countries and seventeen supplementary protection certificates in sixteen countries.
Summary for Esperion Theraps Inc
International Patents: | 44 |
US Patents: | 7 |
Tradenames: | 2 |
Ingredients: | 2 |
NDAs: | 2 |
Drugs and US Patents for Esperion Theraps Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Esperion Theraps Inc | NEXLETOL | bempedoic acid | TABLET;ORAL | 211616-001 | Feb 21, 2020 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | |||||
Esperion Theraps Inc | NEXLIZET | bempedoic acid; ezetimibe | TABLET;ORAL | 211617-001 | Feb 26, 2020 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | |||||
Esperion Theraps Inc | NEXLIZET | bempedoic acid; ezetimibe | TABLET;ORAL | 211617-001 | Feb 26, 2020 | RX | Yes | Yes | 10,912,751 | See Plans and Pricing | See Plans and Pricing | ||||
Esperion Theraps Inc | NEXLETOL | bempedoic acid | TABLET;ORAL | 211616-001 | Feb 21, 2020 | RX | Yes | Yes | 9,624,152 | See Plans and Pricing | See Plans and Pricing | ||||
Esperion Theraps Inc | NEXLIZET | bempedoic acid; ezetimibe | TABLET;ORAL | 211617-001 | Feb 26, 2020 | RX | Yes | Yes | 9,624,152 | See Plans and Pricing | See Plans and Pricing | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Esperion Theraps Inc Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Morocco | 42616 | See Plans and Pricing |
Spain | 2642216 | See Plans and Pricing |
Australia | 2016233485 | See Plans and Pricing |
World Intellectual Property Organization (WIPO) | 2004067489 | See Plans and Pricing |
Hungary | E036646 | See Plans and Pricing |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Esperion Theraps Inc Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2404890 | C20200030 00306 | Estonia | See Plans and Pricing | PRODUCT NAME: BEMPEEDHAPE;REG NO/DATE: EU/1/20/1424 31.03.2020 |
2404890 | C 2020 031 | Romania | See Plans and Pricing | PRODUCT NAME: ACID BEMPEDOIC, SAU O SARE, HIDRAT, SOLVAT ACCEPTABILE FARMACEUTIC SAU AMESTECUL ACESTORA; NATIONAL AUTHORISATION NUMBER: EU/1/20/1424; DATE OF NATIONAL AUTHORISATION: 20200327; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/20/1424; DATE OF FIRST AUTHORISATION IN EEA: 20200327 |
2404890 | 2020/037 | Ireland | See Plans and Pricing | PRODUCT NAME: BEMPEDOIC ACID, OR A PHARMACEUTICALLY ACCEPTABLE SALT, HYDRATE, SOLVATE, OR MIXTURE THEREOF; REGISTRATION NO/DATE: EU/1/20/1424 20200331 |
2404890 | 132020000000112 | Italy | See Plans and Pricing | PRODUCT NAME: ACIDO BEMPEDOICO, O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE, IDRATO, SOLVATO, O LORO MISCELA(NUSTENDI); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/20/1424, 20200331 |
2404890 | 20C1041 | France | See Plans and Pricing | PRODUCT NAME: ACIDE BEMPEDOIQUE, OU UN SEL, HYDRATE, PRODUIT DE SOLVATATION OU MELANGE DE CEUX-CI, PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/20/1424 20200331 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.